New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 18, 2013
10:58 EDTJNJEarnings Preview: Johnson & Johnson at five-year high ahead of Q4 report
Johnson & Johnson (JNJ) is scheduled to report Q4 results before the open on Tuesday January 22, with a conference call scheduled for 8:30 am ET. Johnson & Johnson engages in the research and development, manufacture, and sale of various products in the health care field worldwide... EXPECTATIONS: Analysts are looking for EPS of $1.17 on revenue of $17.67B, according to First Call. The consensus range for EPS is $1.13-$1.23 on revenue of $17.46B-$17.98B... LAST QUARTER: J&J reported Q3 EPS $1.25 against estimates of $1.21 on revenue of $17.1B against estimates of $16.95B. In its Q3 report, the company gave FY12 EPS guidance of $5.05-$5.10 compared to estimates of $5.06. J&J cited by Remicade, Prezista, Velcade as Q3 growth drivers but noted that Q3 sales were hurt by manufacturing suspension at Doxil/Caelyx supplier. During the Q3 earnings conference call CFO Dominic Caruso said U.S. healthcare utilization rates show early signs of stabilization and U.S. joint reconstruction volumes appear to have improved in the latest data but cautioned that although some positive signs can be seen, it is "still too early to signal any meaningful recovery"... STREET RESEARCH: In the last two months, analysts have been generally positive on J&J. On January 4, Deutsche Bank upgraded Johnson & Johnson to Buy from Hold, citing the company's diversification and expectations the company will see improving trends in 2013. The firm raised its price target for shares to $82 from $75. On December 10, Davenport upgraded the shares to Buy from Neutral with an $80 price target... PRICE ACTION: Shares of Johnson and Johnson are trading near a five-year high of ~$73. The shares rose from around $69 per share to $72.74 on Q3 earnings in October, and have since rallied approximately 5% to $72.94.
News For JNJ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 30, 2014
16:39 EDTJNJCMS discloses drug makers' payments to doctors, WSJ says
Subscribe for More Information
15:40 EDTJNJJ&J deal for Alios sets valuation benchmark for Novavax, says Piper Jaffray
Subscribe for More Information
12:40 EDTJNJOn The Fly: Midday Wrap
Subscribe for More Information
12:03 EDTJNJAchillion sinks after Johnson & Johnson buys competitor
The shares of Achillion (ACHN), which has developed a treatment for hepatitis C based on a nucleotide and has been viewed as a potential takeover target by analysts previously, are falling after Johnson & Johnson (JNJ) announced this morning that it had agreed to acquire privately held Alios Biopharma. Alios has developed a number of nucleotide-based hepatitis C treatments, as well as an orally administered antiviral therapy currently in Phase 2 studies for the treatment of infants with respiratory syncytial virus. WHAT'S NEW: Johnson & Johnson said that it had agreed to buy Alios for $1.75B. Alios has developed a number of nucleotides that could be used to treat hepatitis C virus, or HCV. Gilead's (GILD) popular HCV treatment Sovaldi is also a nucleotide and Achillion is developing its own HCV nucleotide treatment. According to The Street's Adam Feuerstein, Achillion's nucleotide is similar in structure to that of Alios. Johnson & Johnson had previously been rumored to be interested in buying Achillion, Feuerstein noted. WHAT'S NOTABLE: Johnson & Johnson said it was "excited" that its acquisition of Alios would enable it to "explore treatment options for a number of viral infections, including RSV, the last of the major pediatric diseases with no available preventive therapy." Novavax (NVAX) is also developing an RSV vaccine and Johnson & Johnson could have considered acquiring it before buying Alios, Feuerstein contended. PRICE ACTION: Near noon, Achillion fell 6% to $10.11, Gilead was down 0.6% to $106.84, Novavax dropped 1% to $4.27, and Johnson & Johnson rose 0.4% to just under $107 per share.
10:30 EDTJNJJ&J could have considered Novavax, Achillion instead of Alios, TheStreet says
Subscribe for More Information
08:31 EDTJNJJohnson & Johnson agrees to acquire Alios BioPharma for $1.75B
Subscribe for More Information
08:16 EDTJNJTetraphase price target raised to $32 from $20 at JMP Securities
Subscribe for More Information
07:30 EDTJNJSachs Associates to hold a conference
14th Annual Biotech in Europe Forum for Global Partnering and Investment to be held in Basel, Switzerland on September 30-October 1.
September 24, 2014
17:59 EDTJNJOdds of Colgate-Palmolive takeover rise amid slew of megamergers, Bloomberg says
Subscribe for More Information
September 23, 2014
08:07 EDTJNJFDA Pediatric Advisory Committee to hold a meeting
Subscribe for More Information
September 22, 2014
07:50 EDTJNJDoctors continue to use morcellators despite FDA warning, J&J halt, WSJ says
Subscribe for More Information
07:07 EDTJNJSynageva appoints Robert Bazemore as COO
Synageva announced the appointment of Robert Bazemore as Chief Operating Officer. Bazemore will oversee the planned global commercial launch of the company's lead program, sebelipase alfa for LAL Deficiency, and will have responsibility for the company's global commercial, market access and medical affairs operations. Bazemore last served at Johnson & Johnson (JNJ) in varoius roles including Vice President, Ethicon New Growth Platforms and President of Janssen Biotech, a part of the Janssen Pharmaceutical Companies of Johnson & Johnson.
September 17, 2014
08:36 EDTJNJJanssen-Cilag announces results from post-hoc canagliflozin analysis
Subscribe for More Information
08:12 EDTJNJJanssen-Cilag announces results from Phase 3 Invokana trial
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use